Literature DB >> 26454650

Efficient gene-targeting in rat embryonic stem cells by CRISPR/Cas and generation of human kynurenine aminotransferase II (KAT II) knock-in rat.

Satoshi Yamamoto1, Yuki Ooshima2, Mitsugu Nakata2, Takashi Yano2, Naoya Nishimura2, Ryuuichi Nishigaki2, Yoshinori Satomi2, Hirokazu Matsumoto2, Yoshio Matsumoto3, Michiyasu Takeyama4.   

Abstract

The relative proportion of kynurenine aminotransferase (KAT) I-IV activities in the brain is similar between humans and rats. Moreover, KAT II is considered to be the main enzyme for kynurenic acid production in the brain. Taken together, human KAT II knock-in (hKAT II KI) rats will become a valuable tool for the evaluation of KAT II targeted drugs as a human mimetic model. Although we initially tried the approach by conventional gene-targeting via embryonic stem cells (ESCs) to generate them, we had to give up the production because of no recombinant ESCs. Accordingly, we developed a method to improve the efficiency of homologous recombination (HR) in ESCs by the combination with the CRISPR/Cas system. Co-electroporation of Cas9 plasmid, single guide RNA plasmid and hKAT II KI vector increased the number of drug-resistant colonies and greatly enhanced the HR efficiency from 0 to 36 %. All the clones which we obtained showed the same sequence as designed. These recombinant clones resulted in chimeras that transmitted the hKAT II KI allele to their offspring. hKAT II KI rats showed no reduction of KATs mRNA expression and the amount of kynurenic acid was similar between the hKAT II KI rats and the wild type in their brains. These results indicate that the methodology presented in this report can overcome the problem encountered in conventional gene-targeting that prevented production of humanized rats.

Entities:  

Keywords:  CRISPR/Cas; Embryonic stem (ES) cells; Genome editing; KAT II; Knock-in; Rat

Mesh:

Substances:

Year:  2015        PMID: 26454650     DOI: 10.1007/s11248-015-9909-1

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  31 in total

1.  Derivation of rat embryonic stem cells and generation of protease-activated receptor-2 knockout rats.

Authors:  Satoshi Yamamoto; Mitsugu Nakata; Reiko Sasada; Yuki Ooshima; Takashi Yano; Tadahiro Shinozawa; Yasuhiro Tsukimi; Michiyasu Takeyama; Yoshio Matsumoto; Tadatoshi Hashimoto
Journal:  Transgenic Res       Date:  2011-10-15       Impact factor: 2.788

2.  CRISPR/Cas-induced double-strand breaks boost the frequency of gene replacements for humanizing the mouse Cnr2 gene.

Authors:  Benjamin Gennequin; David-Marian Otte; Andreas Zimmer
Journal:  Biochem Biophys Res Commun       Date:  2013-11-06       Impact factor: 3.575

3.  Knockout rats generated by embryo microinjection of TALENs.

Authors:  Laurent Tesson; Claire Usal; Séverine Ménoret; Elo Leung; Brett J Niles; Séverine Remy; Yolanda Santiago; Anna I Vincent; Xiangdong Meng; Lei Zhang; Philip D Gregory; Ignacio Anegon; Gregory J Cost
Journal:  Nat Biotechnol       Date:  2011-08-05       Impact factor: 54.908

4.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

Review 5.  Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century.

Authors:  Mario R Capecchi
Journal:  Nat Rev Genet       Date:  2005-06       Impact factor: 53.242

6.  Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos.

Authors:  Yuyu Niu; Bin Shen; Yiqiang Cui; Yongchang Chen; Jianying Wang; Lei Wang; Yu Kang; Xiaoyang Zhao; Wei Si; Wei Li; Andy Peng Xiang; Jiankui Zhou; Xuejiang Guo; Ye Bi; Chenyang Si; Bian Hu; Guoying Dong; Hong Wang; Zuomin Zhou; Tianqing Li; Tao Tan; Xiuqiong Pu; Fang Wang; Shaohui Ji; Qi Zhou; Xingxu Huang; Weizhi Ji; Jiahao Sha
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

7.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 8.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

9.  Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9.

Authors:  Shota Nakade; Takuya Tsubota; Yuto Sakane; Satoshi Kume; Naoaki Sakamoto; Masanobu Obara; Takaaki Daimon; Hideki Sezutsu; Takashi Yamamoto; Tetsushi Sakuma; Ken-ichi T Suzuki
Journal:  Nat Commun       Date:  2014-11-20       Impact factor: 14.919

Review 10.  Generation and utility of genetically humanized mouse models.

Authors:  Nico Scheer; Mike Snaith; C Roland Wolf; Jost Seibler
Journal:  Drug Discov Today       Date:  2013-07-18       Impact factor: 7.851

View more
  4 in total

Review 1.  Update of neurotrophic factors in neurobiology of addiction and future directions.

Authors:  Maryna Koskela; Susanne Bäck; Vootele Võikar; Christopher T Richie; Andrii Domanskyi; Brandon K Harvey; Mikko Airavaara
Journal:  Neurobiol Dis       Date:  2016-05-14       Impact factor: 5.996

Review 2.  From engineering to editing the rat genome.

Authors:  Stephen Meek; Tomoji Mashimo; Tom Burdon
Journal:  Mamm Genome       Date:  2017-07-27       Impact factor: 2.957

Review 3.  Recent Advances in the Production of Genome-Edited Rats.

Authors:  Masahiro Sato; Shingo Nakamura; Emi Inada; Shuji Takabayashi
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

4.  Generation of Hprt-disrupted rat through mouse←rat ES chimeras.

Authors:  Ayako Isotani; Kazuo Yamagata; Masaru Okabe; Masahito Ikawa
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.